Fundraising Overview - The company raised a total of RMB 75,015.00 million through the issuance of 33.34 million shares at RMB 22.50 per share, with actual funds received amounting to RMB 69,139.73 million after deducting issuance costs of RMB 9,097.20 million [1][2] - As of June 30, 2025, the company has used RMB 66,119.20 million of the raised funds, with RMB 54,485.68 million allocated to project expenditures [2][3] Fund Management - The company has established a fundraising management system to ensure the proper storage, approval, usage, and supervision of the raised funds, adhering to principles of regulation, safety, efficiency, and transparency [2][3] - The company has signed tripartite supervision agreements with banks to manage the special accounts for the raised funds, ensuring compliance with regulatory requirements [2][3] Fund Usage - As of June 30, 2025, the company has invested RMB 54,485.68 million in related projects, with no early investments or replacements reported during the reporting period [3][4] - The company has not used idle funds to temporarily supplement working capital or for any other purposes during the reporting period [3][4] Cash Management - The company has approved the use of up to RMB 15,000 million of temporarily idle funds for cash management, investing in safe and liquid financial products [3][4] - As of June 30, 2025, the company has allocated RMB 11,000 million in cash management products, including structured deposits with various banks [3][4] Project Status - The company has adjusted the expected completion date for the "Medical Endoscope Production Base Construction Project" to August 2026, with internal investment structure adjustments approved [3][4] - No changes to the fundraising investment projects have been reported during the reporting period [3][4]
澳华内镜: 关于2025年半年度募集资金存放、管理与实际使用情况的专项报告